1. LOTIS-7 clinical trial data shows 95.5% overall response rate. 2. Enrollment reached 40 patients in LOTIS-7 expansion arm. 3. Cash runway expected into the second half of 2026. 4. Net loss decreased to $38.6 million in Q1 2025. 5. Abstract for LOTIS-5 trial data presentation accepted at EHA2025.
The strong clinical data for ZYNLONTA® indicates significant efficacy, which can positively affect ADCT's stock value. Historical examples suggest strong trial results often lead to stock price increases, as seen with other biotech companies after successful data presentations.
The publication of successful trial results and ongoing cash runway are critical for investor confidence and future growth potential of ADCT.
Positive results from LOTIS-7 and ongoing trials can enhance ADCT's market position over time. Longer-term impacts should arise as these products gain traction in market adoption.
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability.
Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL.
Cash runway expected to fund multiple catalysts into the second half of 2026.
Company to host conference call today at 8:30 a.m. EDT.
LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.
"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA® plus glofitamab to be a best-in-class combination in a dynamic market," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLONTA as we pursue the substantially larger opportunity in earlier lines of DLBCL therapy."
ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2025 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. A live webcast of the call will be available under "Events & Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease.
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Investors: Marcy Graham
Email: marcy.graham@adctherapeutics.com
Phone: +1 650-667-6450
Media: Nicole Riley
Email: nicole.riley@adctherapeutics.com
Phone: +1 862-926-9040